This phase 1 trial was aimed to determine the safety, pharmacokinetics, and preliminary
clinical activity of CYL-02, a nonviral gene therapy product that sensitizes pancreatic cancer …

The aim of the present study was to delineate the functional domains of nociceptin (noc), a
neuropeptide which is structurally related to dynorphin A (dyn). The binding and biological …

To understand how two structurally analogous ligand-receptor systems, the nociceptin/opioid
receptor-like 1 (ORL1) and dynorphin A/κ-opioid receptor 1 (KOR1) systems, achieve …

Pancreatic cancer remains one of the greatest challenges in oncology for which therapeutic
intervention is urgently needed. We previously demonstrated that the intra-tumoral gene …

The ability to repair DNA interstrand cross-links may be an important factor contributing to
mitomycin C (MMC) and cisplatin cytotoxicities. We have assessed the repair of interstrand …

Women generally live longer than men, but women’s longer lives are not necessarily healthy
lives. The aim of this article is to describe the pattern of gender differences in expected …

To date, pancreatic adenocarcinoma (PDAC) can’t be diagnosed early. Consequently, a
majority of patient (80%) display an advanced disease that results in a low resection rate …

Background: the median survival of patients diagnosed with locally advanced or metastatic
pancreatic adenocarcinoma (PDA) is 4 to 6 months. Chemotherapies (gemcitabine, …

Objectives To evaluated the female–male health–survival paradox by estimating the
contribution of women’s mortality advantage versus women’s disability disadvantage. Methods …

… Louis Buscail, Barbara Bournet, Fabienne Vernejoul, Gilles Cambois, Hubert Lulka,
Naima Hanoun, Aline Meulle, Alix Vignolle-Vidoni, Odile Barbey, Fabian Gross, Rosine …